|
Company (Location) |
Company (Location) |
Value (M) |
Type/Product Area |
Terms/Details (Date) |
|
October |
||||
|
Affitech A/S (Copenhagen, Denmark) |
GE Healthcare Life Sciences (Chalfont St. Giles, UK) |
ND |
Exclusive worldwide license for marketing and sales of products contaning recombinant Protein L |
Affitech will receive a royalty on net product sales (10/18) |
|
Alexza Pharmaceuticals Inc. (Mountain View, Calif.) |
Gruppo Ferrer International SA (Barcelona, Spain) |
$10 |
Deal for commercial rights in Europe, Latin America, Russia and the Common-wealth of Independent States countries for Adasuve for schizophrenia or bipolar disorder |
Grupo will handle regulatory filings, and Alexza will receive milestone payments (10/7) |
|
Ausio Pharmaceuticals LLC (Cincinnati) |
Marshall Edwards Inc. (San Diego) |
ND |
Agreement giving Ausio exclusive, worldwide rights under certain Marshall Edwards patents to develop, manufacture and sell products using the isoflavone metabolite equol for applications outside oncology |
Marshall Edwards is entitled to receive royalty payments on sales of Ausio products that contain equol; the deal also gives Marshall Edwards a royalty-free license to certain issued manufacturing-related intellectual property owned by Ausio (10/28) |
|
Gilead Sciences Inc. (Foster City, Calif.) |
Bristol-Myers Squibb Co. (New York) |
ND |
Liense agreement under which BMS will commercialize a fixed-dose HIV combination drug containing BMS' protease inhibitor Reyataz and Gilead's boosting agent cobicistat |
BMS will be responsible for the formulation, manufacturing, development, registration, distribution and commercialization of the combination product, and Gilead will receive an undisclosed royalty (10/27) |
|
Ligand Pharmaceuticals Inc. (La Jolla, Calif.) |
Chiva Pharmaceuticals Inc. (Los Altos Hills, Calif.) |
$4 |
Global licensing deal for Fablyn, approved in the European Union in 2009 to treat osteoporosis in postmenopausal women at increased risk of fracture |
Ligand will receive $4M in licensing payments over the next eight months and is eligible for milestones and royalties on worldwide Fablyn sales (10/11) |
|
Melmed Holdings AG (Switzerland) |
Uluru Inc. (Addison, Texas) |
ND |
Binding letter of intent to license Altrazeal, a product for diabetic foot ulcers |
Melmed will pay a licensing fee plus 25% interest in the Altrazeal marketing subsidiary; Uluru will supply Altrazeal at 30% of the European sales price and will receive royalties on sales within the European territory (10/14) |
|
The Medicines Co. GmbH (Parsippany, N.J.) |
Daiichi Sankyo Deutschland GmbH (Japan) |
ND |
Deal to co-promote Angiox in Germany, beginning Nov. 1 |
The Medicines Co.'s Angiox is indicated in Europe as an anticoagulant for adult patients undergoing percutaneous coronary intervention; financial terms were not disclosed (10/31) |
|
November |
||||
|
Albany Molecular Research Inc. (Albany, N.Y.) |
Eli Lilly and Co. (Indianapolis) |
ND |
Collaboration under which AMRI expects to hire more than 40 synthetic chemists by the third quarter of 2012 to support Lilly's drug discovery programs |
The term of the collaboration is six years (11/9) |
|
Ipsen SA (Paris) |
Britannia Pharmaceuticals Ltd. (Redhill, UK) |
ND |
Ipsen sold North American rights for Apokyn, indicated in the U.S. for acute, intermittent treatment of hypomobility "off" episodes associated with Parkinson's disease |
Ipsen had picked up rights to the drug in 2008 through its acquisition of Vernalis plc; Britannia agreed to pay more than one time the 2010 sales (11/3) |
|
Phosphagenics Ltd. (Melbourne, Australia) |
Themis Medicare Pvt Ltd. (Mumbai, India) |
ND |
Licensing agreement for TPM/diclofenac for the Indian market |
Themis agreed to pay Phosphagenics an up-front fee and double-digit royalties on sales (11/3) |
|
Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International. |
||||
